Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Chronic Heart Failure

Free Subscription Articles published in Eur Heart J Retrieve available abstracts of 362 articles: HTML format

Single Articles

June 2026
1. PAILLARD M
   ERA4Health funded project: liver-heart crosstalk in heart failure.
   Eur Heart J. 2026 Jun 4:ehag360. doi: 10.1093.
   PubMed    
   
   
   May 2026
2. PIEPOLI M, Rosano G, Abreu A, Adamo M, et al
   Prevention of heart failure.
   Eur Heart J. 2026 May 30:ehag362. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. ONO R, Chimura M, Docherty KF, Henderson AD, et al
   Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysis.
   Eur Heart J. 2026 May 28:ehag341. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. GRAPSA J, Almeida AG, Sambola A, Vitale C, et al
   Women's heart centres: a clinical consensus statement of the European Association of Cardiovascular Imaging (EACVI), the European Association of Percutaneous Cardiovascular Interventions (EAPCI), the Heart Failure Association (HFA), and the Associatio
   Eur Heart J. 2026 May 26:ehag350. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. KIM LY, Yuk JS, Kim BG
   Reproductive history, hormonal exposure, and risk of heart failure in postmenopausal women: a Korean nationwide study.
   Eur Heart J. 2026 May 25:ehag380. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. CREA F
   Heart failure and cardiomyopathies: epidemiology, mechanisms, and new therapeutic targets.
   Eur Heart J. 2026;47:2231-2237.
   PubMed    
   
   
   
7. BUTLER J, Khan MS, Friede T, Placzek M, et al
   Mitral transcatheter edge-to-edge repair and outcomes according to baseline health status: the RESHAPE-HF2 trial.
   Eur Heart J. 2026;47:2290-2304.
   PubMed     Abstract available
   
   
   
8. HEYMANS S
   The dual face of lamin A/C cardiomyopathy: risk prediction of heart failure and arrhythmias.
   Eur Heart J. 2026 May 13:ehag215. doi: 10.1093.
   PubMed    
   
   
   
9. CLELAND JGF, Lainscak M, Pellicori P
   Does the global prevalence of heart failure now exceed 600 million people? From guesswork to evidence.
   Eur Heart J. 2026 May 11:ehag331. doi: 10.1093.
   PubMed    
   
   
   
10. HELSETH R, Claggett BL, Bhatt A, Vardeny O, et al
    Viral respiratory tract infections in heart failure: the FINEARTS-HF trial.
    Eur Heart J. 2026 May 11:ehag384. doi: 10.1093.
    PubMed    
    
    
    
11. BAVENDIEK U, Thomas NH, Maier LS, Berliner D, et al
    Digitoxin in heart failure with reduced ejection fraction according to atrial fibrillation status: the DIGIT-HF trial.
    Eur Heart J. 2026 May 10:ehag379. doi: 10.1093.
    PubMed    
    
    
    
12. VAN DER MEER P, van Veldhuisen DJ, Voordes GHD, Tijssen J, et al
    Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in patients with heart failure: the DECISION trial.
    Eur Heart J. 2026 May 10:ehag385. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. NAEIJE R, Ghio S
    Haemodynamic diagnosis of pulmonary vascular disease in heart failure.
    Eur Heart J. 2026 May 6:ehag318. doi: 10.1093.
    PubMed    
    
    
    
14. IACONELLI A, Morsy MI, Friday JM, Pellicori P, et al
    Cancer and heart failure: prevalence, incidence, and prognosis in Scotland.
    Eur Heart J. 2026 May 2:ehag120. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2026
15. VAN DER BIJL MF, Scholte NTB, van Oortmerssen JAE, Roeters van Lennep JE, et al
    Sex differences in pharmacological treatment of heart failure: a meta-analysis of randomized trials.
    Eur Heart J. 2026 Apr 28:ehag311. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. 
    Correction to: Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.
    Eur Heart J. 2026 Apr 16:ehag107. doi: 10.1093.
    PubMed    
    
    
    
17. BAUERSACHS J, Soltani S
    From prescription to persistence: guideline-recommended medical therapy in heart failure with reduced ejection fraction.
    Eur Heart J. 2026 Apr 16:ehag198. doi: 10.1093.
    PubMed    
    
    
    
18. LANDSTEINER I, Verwerft J, Belov D, Verbrugge FH, et al
    Heart failure and preserved ejection fraction: pathophysiology, clinical assessment, and management of exercise intolerance.
    Eur Heart J. 2026 Apr 15:ehag175. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. AJALA A, Dodiyi-Manuel S, Yousef Z
    Improving heart failure outcomes in Africa: the PASCAR-Cardiff University Africa-HF programme.
    Eur Heart J. 2026 Apr 7:ehag097. doi: 10.1093.
    PubMed    
    
    
    
20. LINDBERG F, Uijl A, Benson L, Valente V, et al
    Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription.
    Eur Heart J. 2026 Apr 1:ehag199. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. HUANG H, Hu Y, Li H, Cheng S, et al
    Left bundle branch vs biventricular pacing: mechanistic insights from a canine model.
    Eur Heart J. 2026;47:1595-1605.
    PubMed     Abstract available
    
    
    March 2026
22. ZOCCALI C, De Caterina R, Tuttle KR, Burnier M, et al
    Pre-heart failure in early chronic kidney disease: clinical epidemiology and treatment.
    Eur Heart J. 2026 Mar 31:ehag220. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. REITSMA TH, Lim CE, Gynnild MN, Kaptoge S, et al
    Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model.
    Eur Heart J. 2026 Mar 11:ehag153. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. TORP-PEDERSEN C, Kragholm KH, Kober L
    Risk Scores for Heart Failure: Powerful for Populations, Problematic for the individual Patient.
    Eur Heart J. 2026 Mar 11:ehag183. doi: 10.1093.
    PubMed    
    
    
    
25. 
    Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model.
    Eur Heart J. 2026 Mar 11:ehag154. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. REITSMA TH, Savarese G, Kuzma L, Deo SV, et al
    Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model.
    Eur Heart J. 2026 Mar 11:ehag182. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. BORLAUG BA, Zile MR, Packer M
    Visceral adiposity assessment to enhance risk stratification in heart failure with preserved ejection fraction.
    Eur Heart J. 2026 Mar 6:ehag119. doi: 10.1093.
    PubMed    
    
    
    
28. CHARRON P, Proukhnitzky J, Ben Yaou R, Richard P, et al
    Laminopathies: natural history and risk prediction of heart failure.
    Eur Heart J. 2026 Mar 6:ehag104. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. JIN K, Tang Y, Zhan J, Zhou Y, et al
    Nuclear AGO2 exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis.
    Eur Heart J. 2026 Mar 5:ehag067. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. SANTOVITO D, Weber C
    Argonaute nuclear power: nuclear microRNAs control cardiac metabolism in heart failure with preserved ejection fraction.
    Eur Heart J. 2026 Mar 5:ehaf841. doi: 10.1093.
    PubMed    
    
    
    
31. GALLO G, Volpe M
    Weekly Journal Scan: Estimated efficacy of a combined three-pillar drug treatment in the management of heart failure with mildly reduced or preserved ejection fraction.
    Eur Heart J. 2026 Mar 5:ehag135. doi: 10.1093.
    PubMed    
    
    
    
32. EGOROVA AD
    Addressing the blind spot: identifying heart failure with preserved ejection fraction in adults with congenital heart disease.
    Eur Heart J. 2026 Mar 5:ehag130. doi: 10.1093.
    PubMed    
    
    
    
33. MOURA B, Sousa A, Bayes-Genis A
    Europe's heart failure landscape: the persistent under-recognition of HFpEF.
    Eur Heart J. 2026 Mar 5:ehaf981. doi: 10.1093.
    PubMed    
    
    
    
34. ABA N, Le Teuff G, Fresneau B, Koscielny S, et al
    Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study.
    Eur Heart J. 2026;47:1066-1080.
    PubMed     Abstract available
    
    
    February 2026
35. DE BOER RA, Abdellatif M, Bauersachs J, Roger VL, et al
    Heart failure in the elderly: epidemiology, mechanisms, and management.
    Eur Heart J. 2026 Feb 28:ehag110. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. PACKER M
    Causal role of adipose tissue-derived adipokines in the pathogenesis of heart failure with preserved ejection fraction: experimental demonstration as the basis for clinical targeting.
    Eur Heart J. 2026 Feb 27:ehag029. doi: 10.1093.
    PubMed    
    
    
    
37. LUND LH, Maggioni AP, Crespo-Leiro MG, Laroche C, et al
    Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry.
    Eur Heart J. 2026 Feb 25:ehaf1074. doi: 10.1093/eurheartj/ehaf1074.
    PubMed     Abstract available
    
    
    
38. CREA F
    Heart failure and cardiomypathies: epidemiology and management.
    Eur Heart J. 2026;47:877-882.
    PubMed    
    
    
    
39. DUNCKER D, Marijon E, Bauersachs J
    Sudden cardiac death risk in the early vulnerable phase of heart failure: clarifying the SCD-PROTECT findings.
    Eur Heart J. 2026 Feb 13:ehag054. doi: 10.1093.
    PubMed    
    
    
    
40. CREA F
    Focus on trials: atrial fibrillation, heart failure with reduced ejection fraction, acute coronary syndrome, ischaemic stroke, and renovascular hypertension.
    Eur Heart J. 2026;47:649-654.
    PubMed    
    
    
    
41. BAPTISTA R, Rodrigues AM, Bernardo F, Mendes LL, et al
    Heart failure in the Portuguese population aged >/=50 years: prevalence and phenotypes in the PORTHOS study.
    Eur Heart J. 2026 Feb 5:ehag030. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2026
42. MAEGAARD ERIKSEN V, Lim CW, Thuraiaiyah J, Bjerre Tarp J, et al
    Heart failure with preserved ejection fraction in adults with congenital heart disease.
    Eur Heart J. 2026 Jan 30:ehag017. doi: 10.1093.
    PubMed     Abstract available
    
    
    
43. KRANTZ MJ, Senatore F, Psotka MA, Fiuzat M, et al
    Heart Failure Endpoints in FDA Pivotal Trials.
    Eur Heart J. 2026 Jan 30:ehag069. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. EMANUELSSON F, Benn M
    GLP-1 receptor agonists and heart failure: insights from human genetics.
    Eur Heart J. 2026 Jan 29:ehaf1058. doi: 10.1093/eurheartj/ehaf1058.
    PubMed    
    
    
    
45. HU Y, Zhao Y, Dai N, Zhou Y, et al
    GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization.
    Eur Heart J. 2026 Jan 29:ehaf1066. doi: 10.1093/eurheartj/ehaf1066.
    PubMed     Abstract available
    
    
    
46. ZHANG J, Jiang H, Liu L, Li X, et al
    Histamine N-methyltransferase upregulation, cardiac hypertrophy, and heart failure.
    Eur Heart J. 2026 Jan 22:ehaf1065. doi: 10.1093/eurheartj/ehaf1065.
    PubMed     Abstract available
    
    
    
47. COSTANTINO S, Di Venanzio L, Paneni F
    Histamine N-methyltransferase in heart failure: from metabolic signalling to chromatin remodelling.
    Eur Heart J. 2026 Jan 22:ehaf1062. doi: 10.1093/eurheartj/ehaf1062.
    PubMed    
    
    
    
48. BAUERSACHS J, Zieroth S, de Boer RA
    The year in cardiovascular medicine 2025: the top 10 papers in heart failure.
    Eur Heart J. 2026 Jan 16:ehaf1044. doi: 10.1093/eurheartj/ehaf1044.
    PubMed    
    
    
    
49. DOCHERTY KF, Otto CM, McMurray JJV
    Valvular heart failure: evolving pharmacological approaches.
    Eur Heart J. 2026 Jan 13:ehaf1079. doi: 10.1093/eurheartj/ehaf1079.
    PubMed     Abstract available
    
    
    
50. KIM MC, Ahn JH, Hyun DY, Lim Y, et al
    Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial.
    Eur Heart J. 2026 Jan 6:ehaf924. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. CREA F
    Heart failure and cardiomyopathies: mechanisms, risk prediction, and new therapeutic targets.
    Eur Heart J. 2026;47:1-5.
    PubMed    
    
    
    December 2025
52. PEDICINO D, Liuzzo G
    Weekly Journal Scan: Time to consider influenza vaccination as part of routine heart failure care?
    Eur Heart J. 2025 Dec 19:ehaf932. doi: 10.1093.
    PubMed    
    
    
    
53. ALLIE S, Hahnle J, Sliwa K
    Heart failure in Africa: putting Africa on the map.
    Eur Heart J. 2025 Dec 19:ehaf865. doi: 10.1093.
    PubMed    
    
    
    
54. LAM CSP, Lu Y, Tay WT
    Heart failure and economic resilience: why China's decade-long projection matters.
    Eur Heart J. 2025 Dec 12:ehaf901. doi: 10.1093.
    PubMed    
    
    
    
55. WANG H, Zhou H, Chai K, Yan S, et al
    Heart failure in China: a macroeconomic modelling study of intervention strategies.
    Eur Heart J. 2025 Dec 8:ehaf992. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. SHECHTER A, Shechter M
    Magnesium in heart failure: an old ion with new lessons.
    Eur Heart J. 2025 Dec 5:ehaf955. doi: 10.1093.
    PubMed    
    
    
    
57. YIN Y, Costello RB, Fonarow GC, Heidenreich PA, et al
    Oral magnesium and outcomes in US veterans with heart failure.
    Eur Heart J. 2025 Dec 4:ehaf881. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2025
58. CANNATA A, Packer M
    Vericiguat in heart failure with reduced ejection fraction: being confident in the face of uncertainty.
    Eur Heart J. 2025 Nov 28:ehaf888. doi: 10.1093.
    PubMed    
    
    
    
59. SCHOMMER N, Gendron N, Krauel K, Van Bruggen S, et al
    Neutrophil extracellular traps and peptidylarginine deiminase 4-mediated inflammasome activation link diabetes to cardiorenal injury and heart failure.
    Eur Heart J. 2025 Nov 27:ehaf963. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. VAN LINTHOUT S, Matz I, Gonzalez A, Davis J, et al
    Cardiac fibroblasts in myocardial injury and heart failure.
    Eur Heart J. 2025 Nov 25:ehaf902. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. TAHARA N, Ohta K, Fukumoto Y
    Papillary muscle 18F-fluorodeoxyglucose uptake in heart failure with recovered ejection fraction: reversible metabolic remodelling mimicking cardiac sarcoidosis.
    Eur Heart J. 2025 Nov 18:ehaf898. doi: 10.1093.
    PubMed    
    
    
    
62. CREA F
    Heart failure: focus on genes, kidney, and sudden death.
    Eur Heart J. 2025;46:4449-4452.
    PubMed    
    
    
    
63. CHEN CW, Saeed D, Woo YJ
    Adult heart transplantation in the USA and Western Europe: state of the art review.
    Eur Heart J. 2025 Nov 10:ehaf880. doi: 10.1093.
    PubMed     Abstract available
    
    
    
64. HABIBI H, Gatzoulis MA, Brida M
    Heart failure: terminology matters.
    Eur Heart J. 2025 Nov 7:ehaf775. doi: 10.1093.
    PubMed    
    
    
    
65. CONNORS JM, Gustafsson F, Uriel N, Pagani FD, et al
    Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial.
    Eur Heart J. 2025 Nov 7:ehaf745. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. SCHUBERT MR, Sinner MF
    Understanding atrial cardiomyopathy: a missing link in the prevention of atrial fibrillation, heart failure, and stroke?
    Eur Heart J. 2025 Nov 6:ehaf832. doi: 10.1093.
    PubMed    
    
    
    
67. FATIMA M, Sheikh S, Ammer Z
    Bridging The Gaps In EMPEROR-Preserved: Toward safer and smarter use of Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction.
    Eur Heart J. 2025 Nov 4:ehaf799. doi: 10.1093.
    PubMed    
    
    
    October 2025
68. CREA F
    Improving understanding and management of acute heart failure, myocarditis, pericarditis, amyloidosis, mitochondrial cardiomyopathies, hypertrophic cardiomyopathy, and takotsubo syndrome.
    Eur Heart J. 2025;46:3939-3943.
    PubMed    
    
    
    
69. VAD OB, van Vreeswijk N, Yassin AS, Blaauw Y, et al
    Atrial cardiomyopathy: markers and outcomes.
    Eur Heart J. 2025 Oct 15:ehaf793. doi: 10.1093.
    PubMed     Abstract available
    
    
    
70. LE POLAIN DE WAROUX JB, De Smet MAJ
    Arrhythmic risk and advanced heart failure in dilated cardiomyopathy: a deadly tango.
    Eur Heart J. 2025 Oct 14:ehaf475. doi: 10.1093.
    PubMed    
    
    
    
71. BRAUNWALD E
    The management of heart failure: a brief look into the future.
    Eur Heart J. 2025 Oct 13:ehaf720. doi: 10.1093.
    PubMed    
    
    
    
72. GARCIA-PAVIA P, Gonzalez-Lopez E, Anderson LJ, Cappelli F, et al
    Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association.
    Eur Heart J. 2025 Oct 7:ehaf710. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2025
73. SEFEROVIC PM, Metra M, Mullens W
    Heart Failure 2025 Congress: a recent remarkable success in heart failure.
    Eur Heart J. 2025 Sep 26:ehaf619. doi: 10.1093.
    PubMed    
    
    
    
74. GOTTHARDT M
    RNA-binding proteins as therapeutic targets in cardiac fibrosis and heart failure.
    Eur Heart J. 2025 Sep 9:ehaf644. doi: 10.1093.
    PubMed    
    
    
    
75. NEUEN BL, Vaduganathan M
    Glomerular filtration rate slope in heart failure: ready for prime time?
    Eur Heart J. 2025 Sep 9:ehaf643. doi: 10.1093.
    PubMed    
    
    
    
76. MENTE A, Miller V, Yusuf S
    Diet and heart failure: evidence is limited to make recommendations.
    Eur Heart J. 2025 Sep 9:ehaf521. doi: 10.1093.
    PubMed    
    
    
    
77. CREA F
    Myocarditis after COVID-19, sepsis-induced cardiomyopathy, and haemodynamic assessment of heart failure: focus on the myocardium.
    Eur Heart J. 2025;46:3315-3318.
    PubMed    
    
    
    
78. INKER LA, Neuen BL, McCallum W, Vaduganathan M, et al
    Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions.
    Eur Heart J. 2025 Sep 4:ehaf591. doi: 10.1093.
    PubMed     Abstract available
    
    
    
79. PEIKERT A, Fontana M, Solomon SD, Thum T, et al
    Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment.
    Eur Heart J. 2025 Sep 2:ehaf524. doi: 10.1093.
    PubMed     Abstract available
    
    
    
80. PACKER M
    Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?
    Eur Heart J. 2025 Sep 2:ehaf645. doi: 10.1093.
    PubMed     Abstract available
    
    
    
81. BUTT JH, Solomon SD, McMurray JJV
    Incretin-based therapy for heart failure with reduced ejection fraction: why we need a trial.
    Eur Heart J. 2025 Sep 1:ehaf635. doi: 10.1093.
    PubMed    
    
    
    August 2025
82. CHIMURA M, Docherty KF, Jhund PS, Yang M, et al
    Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.
    Eur Heart J. 2025 Aug 31:ehaf706. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. BORLAUG BA, Zile MR, Kramer CM, Litwin SE, et al
    HFpEF-ABA score is a more useful enrichment tool than natriuretic peptides in heart failure with preserved ejection fraction.
    Eur Heart J. 2025 Aug 31:ehaf663. doi: 10.1093.
    PubMed    
    
    
    
84. ANKER MS, Mahabadi AA, Totzeck M, Tewes M, et al
    Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial).
    Eur Heart J. 2025 Aug 30:ehaf705. doi: 10.1093.
    PubMed     Abstract available
    
    
    
85. BUTLER J, Fioretti F, McMullan CJ, Anstrom KJ, et al
    Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.
    Eur Heart J. 2025 Aug 30:ehaf655. doi: 10.1093.
    PubMed     Abstract available
    
    
    
86. ROSSELLO X, Dominguez-Rodriguez A, Latini R, Sanchez PL, et al
    Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial.
    Eur Heart J. 2025 Aug 30:ehaf673. doi: 10.1093.
    PubMed     Abstract available
    
    
    
87. DOCHERTY KF, Heywood B, Bayes-Genis A, Campbell RT, et al
    Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure.
    Eur Heart J. 2025 Aug 29:ehaf675. doi: 10.1093.
    PubMed     Abstract available
    
    
    
88. MORA-AYESTARAN N, Ochoa JP, Gomez-Gonzalez C, Navarro-Penalver M, et al
    Arrhythmic genotypes in dilated cardiomyopathy and risk of advanced heart failure.
    Eur Heart J. 2025 Aug 29:ehaf605. doi: 10.1093.
    PubMed     Abstract available
    
    
    
89. LURZ P, Hahn RT, Kodali S, Makkar R, et al
    Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial.
    Eur Heart J. 2025 Aug 29:ehaf676. doi: 10.1093.
    PubMed     Abstract available
    
    
    
90. GUALANDRO DM, Masip J, Halvorsen S, Price S, et al
    Acute heart failure in non-cardiac surgery.
    Eur Heart J. 2025 Aug 21:ehaf559. doi: 10.1093.
    PubMed     Abstract available
    
    
    
91. 
    Correction to: Telemonitoring for heart failure: a meta-analysis.
    Eur Heart J. 2025 Aug 21:ehaf509. doi: 10.1093.
    PubMed    
    
    
    
92. ABDIN A, Sawan N, Katbeh A
    Uniting for heart failure awareness in Syria.
    Eur Heart J. 2025 Aug 21:ehaf500. doi: 10.1093.
    PubMed    
    
    
    
93. CREA F
    Comprehensive update on heart failure and cardiomyopathies: from epidemiology to mechanisms and management.
    Eur Heart J. 2025;46:3027-3031.
    PubMed    
    
    
    
94. SEGAN L, Kistler PM, Nanayakkara S, Taylor A, et al
    Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial.
    Eur Heart J. 2025 Aug 12:ehaf563. doi: 10.1093.
    PubMed     Abstract available
    
    
    
95. ADAMO M, Pagnesi M, Ajmone Marsan N, Bauersachs J, et al
    Heart failure with reduced ejection fraction and ventricular secondary mitral regurgitation: a holistic approach.
    Eur Heart J. 2025 Aug 1:ehaf480. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2025
96. KOBAYASHI M, Bayes-Genis A, Duarte K, McMurray JJV, et al
    Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction.
    Eur Heart J. 2025 Jul 30:ehaf457. doi: 10.1093.
    PubMed     Abstract available
    
    
    
97. 
    Correction to: Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial.
    Eur Heart J. 2025 Jul 24:ehaf512. doi: 10.1093.
    PubMed    
    
    
    
98. KANEKO T, Kagiyama N, Okazaki S, Amano M, et al
    Transcatheter edge-to-edge repair vs medical therapy in atrial functional mitral regurgitation: a propensity score-based comparison from the OCEAN-Mitral and REVEAL-AFMR registries.
    Eur Heart J. 2025 Jul 9:ehaf511. doi: 10.1093.
    PubMed     Abstract available
    
    
    
99. GIANNAKOULAS G, Farmakis IT, Hobohm L, Verbrugge FH, et al
    Acute right ventricular failure: pathophysiology, aetiology, assessment, and management.
    Eur Heart J. 2025;46:2520-2535.
    PubMed     Abstract available
    
    
    
100. CREA F
     Heart failure: evolving management and new therapeutic targets.
     Eur Heart J. 2025;46:2359-2363.
     PubMed    
     
     
     
101. HEIMERL M, Erschow S, Muller-Olling M, Manstein DJ, et al
     Cardiac dysfunction related to cardiac mRNA and protein traffic impairment due to reduced unconventional motor protein myosin-5b expression.
     Eur Heart J. 2025;46:2437-2454.
     PubMed     Abstract available
     
     
     June 2025
102. LI Y, Wang Y, Zhang C
     Electrical storm and refractory heart failure necessitating left ventricular assist device in ischaemic cardiomyopathy with apical aneurysm.
     Eur Heart J. 2025 Jun 16:ehaf403. doi: 10.1093.
     PubMed    
     
     
     
103. ZEDER K, Mak S, Galie N, Rosenkranz S, et al
     Right heart catheterization in heart failure: indications, interpretation, and pitfalls.
     Eur Heart J. 2025 Jun 16:ehaf322. doi: 10.1093.
     PubMed     Abstract available
     
     
     
104. LINDE C, Packer M, Bauersachs J
     Great debate: ablation of atrial fibrillation should be performed in patients with heart failure with reduced ejection fraction.
     Eur Heart J. 2025 Jun 10:ehaf182. doi: 10.1093.
     PubMed    
     
     
     
105. RYAN M, Petrie MC, Kontopantelis E, Dodd M, et al
     Medical therapy and outcomes in REVIVED-BCIS2 and STICHES: an individual patient data analysis.
     Eur Heart J. 2025;46:2052-2062.
     PubMed     Abstract available
     
     
     
106. LI L, Guo J, Feng J, Li T, et al
     Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure.
     Eur Heart J. 2025 Jun 5:ehaf370. doi: 10.1093.
     PubMed     Abstract available
     
     
     
107. HAYNES N, Spatz ES
     The invisible costs of heart failure: a societal toll.
     Eur Heart J. 2025 Jun 3:ehaf223. doi: 10.1093.
     PubMed    
     
     
     
108. CHASELING GK, Uchmanowicz I, Back M, Miro O, et al
     Heat extremes and cardiovascular diseases: a scientific statement of the Association of Cardiovascular Nursing & Allied Professions, Association for Acute Cardiovascular Care, European Association of Preventive Cardiology, Heart Failure Association, E
     Eur Heart J. 2025 Jun 3:ehaf326. doi: 10.1093.
     PubMed     Abstract available
     
     
     
109. NITSCHE C, Dobner S, Rosenblum HR, Patel KP, et al
     Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis.
     Eur Heart J. 2025 Jun 2:ehaf362. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2025
110. DARVISH M, Shakoor A, Feyz L, Schaap J, et al
     Heart failure: assessment of the global economic burden.
     Eur Heart J. 2025 May 30:ehaf323. doi: 10.1093.
     PubMed     Abstract available
     
     
     
111. TUAL-CHALOT S, Stellos K
     Unravelling heart failure cellular signalling heterogeneity with spatial transcriptomics.
     Eur Heart J. 2025 May 30:ehaf311. doi: 10.1093.
     PubMed    
     
     
     
112. BAUDRY G, Pereira O, Roubille F, Villaceque M, et al
     Cardiologist follow-up and improved outcomes of heart failure: a French nationwide cohort.
     Eur Heart J. 2025 May 18:ehaf218. doi: 10.1093.
     PubMed     Abstract available
     
     
     
113. LUND LH
     Heart failure: the need for cardiologist-guided follow-up to improve outcomes.
     Eur Heart J. 2025 May 18:ehaf229. doi: 10.1093.
     PubMed    
     
     
     
114. CREA F
     New treatments and biomarkers in heart failure, hypertrophic cardiomyopathy, and familial hypercholesterolaemia.
     Eur Heart J. 2025;46:1777-1780.
     PubMed    
     
     
     
115. LEE SE, Joo JH, Hwang HS, Chen SF, et al
     Spatial transcriptional landscape of human heart failure.
     Eur Heart J. 2025 May 8:ehaf272. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2025
116. WIGGERS H
     Fatty acids in heart failure patients: friend or foe?
     Eur Heart J. 2025 Apr 25:ehaf247. doi: 10.1093.
     PubMed    
     
     
     
117. VERBRUGGE FH
     Natriuretic targets in acute heart failure with volume overload: are we misguided?
     Eur Heart J. 2025 Apr 25:ehaf243. doi: 10.1093.
     PubMed    
     
     
     
118. MARQUES P, Ferreira JP
     Obesity, metrics of central adiposity, and prognostic significance in heart failure with preserved and mildly reduced ejection fraction.
     Eur Heart J. 2025 Apr 25:ehaf198. doi: 10.1093.
     PubMed    
     
     
     
119. IVEY-MIRANDA JB, Rao VS, Cox ZL, Moreno-Villagomez J, et al
     Natriuretic response prediction equation for use with oral diuretics in heart failure.
     Eur Heart J. 2025 Apr 24:ehaf268. doi: 10.1093.
     PubMed     Abstract available
     
     
     
120. MALGIE J, Wilde MI, Brunner-La Rocca HP, Emans ME, et al
     Newly diagnosed heart failure with reduced ejection fraction: timing, sequencing, and titration of guideline-recommended medical therapy.
     Eur Heart J. 2025 Apr 24:ehaf244. doi: 10.1093.
     PubMed     Abstract available
     
     
     
121. DOCHERTY KF, Shen L, McMurray JJV
     Advocating for better care of patients with heart failure.
     Eur Heart J. 2025 Apr 24:ehaf224. doi: 10.1093.
     PubMed    
     
     
     
122. CREA F
     Focus on heart failure: sex-related differences, new light shed on SGLT2i mechanism of action, and heart failure after myocardial infarction.
     Eur Heart J. 2025;46:1457-1461.
     PubMed    
     
     
     
123. PEDICINO D, Volpe M
     Weekly Journal Scan: a deep insight into aldosterone antagonism across the heart failure spectrum.
     Eur Heart J. 2025 Apr 15:ehaf233. doi: 10.1093.
     PubMed    
     
     
     
124. VELTMANN C, Duncker D, Maier LS
     Management of de novo heart failure with reduced ejection fraction: guideline-recommended medical therapy comes first.
     Eur Heart J. 2025 Apr 9:ehaf157. doi: 10.1093.
     PubMed    
     
     
     
125. AKIN I, Hamdani N, El-Battrawy I
     Multimodal approaches for targeted treatment of heart failure.
     Eur Heart J. 2025 Apr 9:ehaf156. doi: 10.1093.
     PubMed    
     
     
     
126. XIONG G
     Post-capillary pulmonary hypertension in heart failure: addressing statistical and methodological issues in research.
     Eur Heart J. 2025 Apr 8:ehae812. doi: 10.1093.
     PubMed    
     
     
     
127. FAUVEL C, Lamblin N
     Post-capillary Pulmonary Hypertension in Heart Failure is associated with higher mortality and morbidity risk: not just a matter of << hasard >>.
     Eur Heart J. 2025 Apr 8:ehae814. doi: 10.1093.
     PubMed    
     
     
     
128. OSTROMINSKI JW, Hojbjerg Lassen MC, Claggett BL, Miao ZM, et al
     Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease.
     Eur Heart J. 2025;46:1321-1331.
     PubMed     Abstract available
     
     
     March 2025
129. SEN P, Sorop O, Merkus D
     Increasing heart rate in heart failure with preserved ejection fraction: a sensible way to go?
     Eur Heart J. 2025 Mar 25:ehaf109. doi: 10.1093.
     PubMed    
     
     
     
130. VAN LOON T, Vernooy K, Lumens J
     Rate acceleration in heart failure with preserved ejection fraction: towards different strokes for different folks.
     Eur Heart J. 2025 Mar 25:ehaf110. doi: 10.1093.
     PubMed    
     
     
     
131. SOUZA ACDAH, Troschel AS, Marquardt JP, Hadzic I, et al
     Skeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomes.
     Eur Heart J. 2025;46:1112-1123.
     PubMed     Abstract available
     
     
     
132. CREA F
     Focus on amyloidosis, peripartum cardiomyopathy, and heart failure prediction by artificial intelligence applied to ECG.
     Eur Heart J. 2025;46:987-990.
     PubMed    
     
     
     
133. SLIWA K, Jackson A, Viljoen C, Damasceno A, et al
     Pregnancies in women after peri-partum cardiomyopathy: the global European Society of Cardiology EuroObservational Research Programme Peri-Partum Cardiomyopathy Registry.
     Eur Heart J. 2025;46:1031-1040.
     PubMed     Abstract available
     
     
     
134. GONZALEZ-LOPEZ E, Maurer MS, Garcia-Pavia P
     Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine.
     Eur Heart J. 2025;46:999-1013.
     PubMed     Abstract available
     
     
     
135. BOHM M, Butler J, Coats A, Lauder L, et al
     Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
     Eur Heart J. 2025 Mar 4:ehae938. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2025
136. LINDBERG F, Savarese G
     Opportunities and challenges in preventing heart failure: when is risk modifiable?
     Eur Heart J. 2025 Feb 28:ehaf042. doi: 10.1093.
     PubMed    
     
     
     
137. STORK S
     Suspected heart failure: a clinical pattern that calls for action.
     Eur Heart J. 2025 Feb 25:ehae846. doi: 10.1093.
     PubMed    
     
     
     
138. ABDELLATIF M, Vasques-Novoa F, Trummer-Herbst V, Durand S, et al
     Autophagy is required for the therapeutic effects of the NAD+ precursor nicotinamide in obesity-related heart failure with preserved ejection fraction.
     Eur Heart J. 2025 Feb 25:ehaf062. doi: 10.1093.
     PubMed    
     
     
     
139. GREEN PG, Watson WD, Bussmann BM, De Maria GL, et al
     Metabolic flexibility and reverse remodelling of the failing human heart.
     Eur Heart J. 2025 Feb 25:ehaf033. doi: 10.1093.
     PubMed     Abstract available
     
     
     
140. DOI S, Reddy YNV, Jensen MD, Smith JR, et al
     Dapagliflozin and ventilatory control during exercise in heart failure with preserved ejection fraction: the CAMEO-DAPA trial.
     Eur Heart J. 2025 Feb 19:ehaf027. doi: 10.1093.
     PubMed    
     
     
     
141. FIORETTI F, Nair AP, Anker SD, Borlaug BA, et al
     Therapeutic left-to-right shunting in heart failure.
     Eur Heart J. 2025 Feb 13:ehaf120. doi: 10.1093.
     PubMed     Abstract available
     
     
     
142. ANDERSON L, Bayes-Genis A, Bodegard J, Mullin K, et al
     Suspected de novo heart failure in outpatient care: the REVOLUTION HF study.
     Eur Heart J. 2025 Feb 12:ehaf034. doi: 10.1093.
     PubMed     Abstract available
     
     
     
143. LAKHAL-LITTLETON S
     Anaemia, neurohormonal activation, and myocardial iron depletion in heart failure: can this vicious circle be broken?
     Eur Heart J. 2025 Feb 5:ehae798. doi: 10.1093.
     PubMed    
     
     
     
144. ANGERMANN CE, Sehner S, Gerhardt LMS, Santos-Gallego CG, et al
     Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial.
     Eur Heart J. 2025 Feb 5:ehae917. doi: 10.1093.
     PubMed     Abstract available
     
     
     January 2025
145. BUTLER J, Hammonds K, Talha KM, Alhamdow A, et al
     Incident heart failure and recurrent coronary events following acute myocardial infarction.
     Eur Heart J. 2025 Jan 28:ehae885. doi: 10.1093.
     PubMed     Abstract available
     
     
     
146. PEIKERT A, Vaduganathan M, Claggett BL, Kulac IJ, et al
     Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial.
     Eur Heart J. 2025 Jan 28:ehaf057. doi: 10.1093.
     PubMed     Abstract available
     
     
     
147. MATSUMOTO S, Ohno Y, Noda S, Miyamoto J, et al
     Tricuspid regurgitation and outcomes in mitral valve transcatheter edge-to-edge repair.
     Eur Heart J. 2025 Jan 28:ehae924. doi: 10.1093.
     PubMed     Abstract available
     
     
     
148. BAUERSACHS J, Zieroth S, de Boer RA
     The year in cardiovascular medicine 2024: the top 10 papers in heart failure.
     Eur Heart J. 2025 Jan 23:ehaf017. doi: 10.1093.
     PubMed    
     
     
     
149. LIUZZO G, Patrono C
     Weekly Journal Scan: Have we reached the SUMMIT of incretin treatment of heart failure with preserved ejection fraction and obesity?
     Eur Heart J. 2025 Jan 21:ehaf013. doi: 10.1093.
     PubMed    
     
     
     
150. GASPERETTI A, Carrick RT, Protonotarios A, Murray B, et al
     Clinical features and outcomes in carriers of pathogenic desmoplakin variants.
     Eur Heart J. 2025;46:362-376.
     PubMed     Abstract available
     
     
     
151. ANTONIADES C, Chan K
     Using artificial intelligence to spot heart failure from ECGs: is it prime time?
     Eur Heart J. 2025 Jan 15:ehae906. doi: 10.1093.
     PubMed    
     
     
     
152. DHINGRA LS, Aminorroaya A, Sangha V, Pedroso AF, et al
     Heart failure risk stratification using artificial intelligence applied to electrocardiogram images: a multinational study.
     Eur Heart J. 2025 Jan 13:ehae914. doi: 10.1093.
     PubMed     Abstract available
     
     
     
153. WILKINSON C, Bhatty A, Batra G, Aktaa S, et al
     Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).
     Eur Heart J. 2025;46:190-214.
     PubMed     Abstract available
     
     
     December 2024
154. VAN ESSEN BJ, Emmens JE, Tromp J, Ouwerkerk W, et al
     Sex-specific risk factors for new-onset heart failure: the PREVEND study at 25 years.
     Eur Heart J. 2024 Dec 30:ehae868. doi: 10.1093.
     PubMed     Abstract available
     
     
     
155. VAN LOON T, Rijks J, van Koll J, Wolffs J, et al
     Accelerated atrial pacing reduces left-heart filling pressure: a combined clinical-computational study.
     Eur Heart J. 2024;45:4953-4964.
     PubMed     Abstract available
     
     
     
156. FERREIRA JP, Zannad F, Vasques-Novoa F, Neves JS, et al
     Anaemia, erythrocytosis, and empagliflozin in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
     Eur Heart J. 2024 Dec 6:ehae864. doi: 10.1093.
     PubMed    
     
     
     
157. CREA F
     Focus on adult congenital heart disease and on the role of inflammation and clonal haematopoiesis in heart failure.
     Eur Heart J. 2024;45:4773-4776.
     PubMed    
     
     
     November 2024
158. AI L, de Freitas Germano J, Huang C, Aniag M, et al
     Enhanced Parkin-mediated mitophagy mitigates adverse left ventricular remodelling after myocardial infarction: role of PR-364.
     Eur Heart J. 2024 Nov 27:ehae782. doi: 10.1093.
     PubMed     Abstract available
     
     
     
159. OMEROVIC E, Ramunddal T, Petursson P, Angeras O, et al
     Percutaneous vs. surgical revascularization of non-ST-segment elevation myocardial infarction with multivessel disease: the SWEDEHEART registry.
     Eur Heart J. 2024 Nov 27:ehae700. doi: 10.1093.
     PubMed     Abstract available
     
     
     
160. MEYER M
     Accelerated pacing as a treatment for heart failure with preserved ejection fraction and atrial fibrillation?
     Eur Heart J. 2024 Nov 26:ehae766. doi: 10.1093.
     PubMed    
     
     
     
161. MAZHAR F, Faucon AL, Fu EL, Szummer KE, et al
     Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease.
     Eur Heart J. 2024;45:4719-4730.
     PubMed     Abstract available
     
     
     
162. 
     Correction to: Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score.
     Eur Heart J. 2024 Nov 18:ehae818. doi: 10.1093.
     PubMed    
     
     
     
163. EL BEZE N, Steg PG
     Heart failure and revascularization: which method to choose and should we even do it?
     Eur Heart J. 2024 Nov 11:ehae715. doi: 10.1093.
     PubMed    
     
     
     
164. WANDEL S, Desai AS, Chen CW, McMurray JJV, et al
     Centrally adjudicated vs. investigator-reported outcomes in randomized heart failure trials.
     Eur Heart J. 2024 Nov 9:ehae753. doi: 10.1093.
     PubMed     Abstract available
     
     
     
165. CREA F
     Evolving therapeutic approaches to aortic stenosis, tricuspid regurgitation, hypertrophic cardiomyopathy, and acute heart failure.
     Eur Heart J. 2024;45:4451-4455.
     PubMed    
     
     
     
166. SEFEROVIC PM, Coats AJS, Filippatos G
     The ESC Textbook of Heart Failure: breaking the new educational frontier.
     Eur Heart J. 2024 Nov 6:ehad897. doi: 10.1093.
     PubMed    
     
     
     October 2024
167. PEDICINO D, Vergallo R
     Weekly Journal Scan: RESHAPing potential treatment indications for functional mitral regurgitation in heart failure.
     Eur Heart J. 2024 Oct 29:ehae727. doi: 10.1093.
     PubMed    
     
     
     
168. KARAKASIS P, Pamporis K, Siontis KC, Theofilis P, et al
     Major clinical outcomes in symptomatic vs. asymptomatic atrial fibrillation: a meta-analysis.
     Eur Heart J. 2024 Oct 21:ehae694. doi: 10.1093.
     PubMed     Abstract available
     
     
     
169. TAYLOR J
     New editor-in-chief for European Society of Cardiology heart failure journals.
     Eur Heart J. 2024 Oct 16:ehae644. doi: 10.1093.
     PubMed    
     
     
     
170. MAACK C, Vilahur G, Ruiz-Meana M, Hausenloy D, et al
     New COST Action 'EUropean network to tackle METAbolic alterations in HEART failure' (EU-METAHEART).
     Eur Heart J. 2024 Oct 16:ehae457. doi: 10.1093.
     PubMed    
     
     
     
171. VOLPE M, Galiuto L
     Weekly Journal Scan: FINEARTS-HF supports the role of aldosterone antagonism in the management of heart failure with mildly reduced or preserved ejection fraction.
     Eur Heart J. 2024 Oct 11:ehae679. doi: 10.1093.
     PubMed    
     
     
     
172. CREA F
     New light shed on the treatment of heart failure and on novel therapeutic targets.
     Eur Heart J. 2024;45:3775-3779.
     PubMed    
     
     
     
173. ROSENGREN A
     Loop diuretics in cardiovascular disease: friend or foe?
     Eur Heart J. 2024;45:3850-3852.
     PubMed    
     
     
     September 2024
174. TALHA KM, Metra M, Butler J
     Heart failure with preserved ejection fraction: underdiagnosed and undertreated in patients with tricuspid regurgitation.
     Eur Heart J. 2024 Sep 9:ehae544. doi: 10.1093.
     PubMed    
     
     
     
175. HAVERS-BORGERSEN E, Hartwell D, Ekelund C, Butt JH, et al
     Endometriosis and Long-Term Cardiovascular Risk: A Nationwide Danish study.
     Eur Heart J. 2024 Sep 2:ehae563. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2024
176. BHATT AS, Vaduganathan M
     Implementing Medical Therapy During Worsening Heart Failure.
     Eur Heart J. 2024 Aug 31:ehae566. doi: 10.1093.
     PubMed    
     
     
     
177. TANAKA A, Kida K, Matsue Y, Imai T, et al
     In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial.
     Eur Heart J. 2024 Aug 31:ehae561. doi: 10.1093.
     PubMed     Abstract available
     
     
     
178. PASCUAL-FIGAL D, Nunez J, Perez-Martinez MT, Gonzalez-Juanatey JR, et al
     Colchicine in acutely decompensated heart failure: the COLICA trial.
     Eur Heart J. 2024 Aug 30:ehae538. doi: 10.1093.
     PubMed     Abstract available
     
     
     
179. TARDIF JC, Ouellette K, Boulet J
     Colchicine improves outcomes in coronary disease, but will it in heart failure?
     Eur Heart J. 2024 Aug 30:ehae612. doi: 10.1093.
     PubMed    
     
     
     
180. MINISTRINI S, Tirandi A
     Von Willebrand factor in inflammation and heart failure: beyond thromboembolic and bleeding risk.
     Eur Heart J. 2024 Aug 28:ehae543. doi: 10.1093.
     PubMed    
     
     
     
181. VON HAEHLING S, Doehner W, Evertz R, Garfias-Veitl T, et al
     Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial.
     Eur Heart J. 2024 Aug 26:ehae479. doi: 10.1093.
     PubMed     Abstract available
     
     
     
182. KITTIPIBUL V, Mentz RJ
     Intravenous iron therapy in heart failure with preserved ejection fraction: how far have we walked?
     Eur Heart J. 2024 Aug 26:ehae490. doi: 10.1093.
     PubMed    
     
     
     
183. REDDY YNV, Melenovsky V, Asokan AK, Haluzik M, et al
     Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction.
     Eur Heart J. 2024 Aug 21:ehae534. doi: 10.1093.
     PubMed    
     
     
     
184. MANG G, Chen J, Sun P, Ma R, et al
     Von Willebrand factor exacerbates heart failure through formation of neutrophil extracellular traps.
     Eur Heart J. 2024 Aug 21:ehae517. doi: 10.1093.
     PubMed     Abstract available
     
     
     
185. CREA F
     Hot topics in thromboembolic risk prevention, heart failure monitoring, and cardiomyopathy risk stratification.
     Eur Heart J. 2024;45:2899-2903.
     PubMed    
     
     
     
186. 
     Correction to: Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.
     Eur Heart J. 2024 Aug 20:ehae243. doi: 10.1093.
     PubMed    
     
     
     
187. ROSENKRANZ S, Hoeper MM, Maron BA
     Pulmonary hypertension in heart failure: the good, the bad, and the ugly.
     Eur Heart J. 2024 Aug 12:ehae518. doi: 10.1093.
     PubMed    
     
     
     
188. CREA F
     Heart failure and ischaemic heart disease: new challenges and opportunities.
     Eur Heart J. 2024;45:2681-2685.
     PubMed    
     
     
     
189. RIVERO-SANTANA B, Saldana-Garcia J, Caro-Codon J, Zamora P, et al
     Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score.
     Eur Heart J. 2024 Aug 6:ehae496. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2024
190. FAUVEL C, Damy T, Berthelot E, Bauer F, et al
     Post-capillary pulmonary hypertension in heart failure: impact of current definition in the PH-HF multicentre study.
     Eur Heart J. 2024 Jul 26:ehae467. doi: 10.1093.
     PubMed     Abstract available
     
     
     
191. OSTROMINSKI JW, Chatur S, Vaduganathan M
     STEPping down diuretic therapy with semaglutide in obesity-related heart failure with preserved ejection fraction: decongestion or disease modification?
     Eur Heart J. 2024 Jul 26:ehae410. doi: 10.1093.
     PubMed    
     
     
     
192. CREA F
     Focus on acute myocardial infarction, sex-related differences in coronary bypass surgery, inflammation in heart failure, and infective endocarditis in prosthetic valves.
     Eur Heart J. 2024;45:2463-2467.
     PubMed    
     
     
     
193. STORK S
     Pulmonary artery pressure-guided heart failure care: the setting matters.
     Eur Heart J. 2024 Jul 19:ehae441. doi: 10.1093.
     PubMed    
     
     
     
194. PEDICINO D, Volpe M
     Weekly Journal Scan: a 'thousand-mile' journey in obesity-related heart failure treatment begins with a few STEPs.
     Eur Heart J. 2024 Jul 10:ehae427. doi: 10.1093.
     PubMed    
     
     
     
195. OSTROMINSKI JW, Solomon SD, Vaduganathan M
     Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.
     Eur Heart J. 2024 Jul 10:ehae414. doi: 10.1093.
     PubMed    
     
     
     
196. ZANNAD F, Ferreira JP
     Proteomics for understanding progression to heart failure in chronic kidney disease: promising but still not there.
     Eur Heart J. 2024 Jul 9:ehae399. doi: 10.1093.
     PubMed    
     
     
     
197. CREA F
     A new classification of iron-deficient heart failure, sex-related differences in the management of atrial fibrillation and mitral regurgitation, and an update on the genetics of Brugada syndrome.
     Eur Heart J. 2024;45:2267-2270.
     PubMed    
     
     
     
198. CREA F
     Innovative therapeutic targets in cardio-oncology and a Great Debate in heart failure.
     Eur Heart J. 2024;45:2171-2174.
     PubMed    
     
     
     
199. BOROVAC JA
     Guideline-recommended medical therapy for de novo heart failure with reduced ejection fraction: be patient waiting for reverse remodelling.
     Eur Heart J. 2024 Jul 8:ehae400. doi: 10.1093.
     PubMed    
     
     
     
200. BECHER N, Metzner A, Toennis T, Kirchhof P, et al
     Atrial fibrillation burden: a new outcome predictor and therapeutic target.
     Eur Heart J. 2024 Jul 2:ehae373. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2024
201. HOLFELD J, Nagele F, Polzl L, Engler C, et al
     Cardiac shockwave therapy in addition to coronary bypass surgery improves myocardial function in ischaemic heart failure: the CAST-HF trial.
     Eur Heart J. 2024 Jun 20:ehae341. doi: 10.1093.
     PubMed     Abstract available
     
     
     
202. VELTMANN C, Duncker D, Doering M, Gummadi S, et al
     Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study.
     Eur Heart J. 2024 Jun 12:ehae334. doi: 10.1093.
     PubMed     Abstract available
     
     
     
203. FRIDAY JM, Cleland JG, Pellicori P, Wolters M, et al
     Loop diuretic utilisation with or without heart failure: impact on prognosis.
     Eur Heart J. 2024 Jun 7:ehae345. doi: 10.1093.
     PubMed     Abstract available
     
     
     
204. CREA F
     Focus on emerging cancer drugs, artificial intelligence applied to imaging, and a new therapeutic target in heart failure.
     Eur Heart J. 2024;45:1959-1962.
     PubMed    
     
     
     
205. BHAVE S, Rodriguez V, Poterucha T, Mutasa S, et al
     Deep learning to detect left ventricular structural abnormalities in chest X-rays.
     Eur Heart J. 2024;45:2002-2012.
     PubMed     Abstract available
     
     
     
206. ABBAS N, Haas JA, Xiao K, Fuchs M, et al
     Inhibition of miR-21: cardioprotective effects in human failing myocardium ex vivo.
     Eur Heart J. 2024;45:2016-2018.
     PubMed    
     
     
     
207. 
     Correction to: Epidemiology of heart failure in young adults: a French nationwide cohort study.
     Eur Heart J. 2024 Jun 4:ehae187. doi: 10.1093.
     PubMed    
     
     
     May 2024
208. PACKER M, Cleland JGF, Bauersachs J
     Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction.
     Eur Heart J. 2024 May 28:ehae300. doi: 10.1093.
     PubMed    
     
     
     
209. YANO T, Takeda A, Murayama K
     A hidden cause of middle-aged onset heart failure with preserved ejection fraction: a GTPBP3 variant.
     Eur Heart J. 2024 May 24:ehae309. doi: 10.1093.
     PubMed    
     
     
     
210. FEINSTEIN MJ
     Human Immunology of Heart Failure: Deconstructing Inflammatory Risk.
     Eur Heart J. 2024 May 21:ehae339. doi: 10.1093.
     PubMed    
     
     
     
211. SUN J, Yao J, Olen O, Halfvarson J, et al
     Risk of heart failure in inflammatory bowel disease: a Swedish population-based study.
     Eur Heart J. 2024 May 21:ehae338. doi: 10.1093.
     PubMed     Abstract available
     
     
     
212. 
     Correction to: Anthracycline therapy induces an early decline of cardiac contractility with transient edema in low risk patients with breast cancer.
     Eur Heart J. 2024;45:1764.
     PubMed    
     
     
     
213. DUBIN RF, Deo R, Ren Y, Wang J, et al
     Incident heart failure in chronic kidney disease: proteomics informs biology and risk stratification.
     Eur Heart J. 2024 May 17:ehae288. doi: 10.1093.
     PubMed     Abstract available
     
     
     
214. AVIERINOS JF, Tribouilloy C, Bursi F, Grigioni F, et al
     Degenerative mitral regurgitation due to flail leaflet: sex-related differences in presentation, management, and outcomes.
     Eur Heart J. 2024 May 16:ehae265. doi: 10.1093.
     PubMed     Abstract available
     
     
     
215. SHAH SJ, Sharma K, Borlaug BA, Butler J, et al
     Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.
     Eur Heart J. 2024 May 13:ehae322. doi: 10.1093.
     PubMed     Abstract available
     
     
     
216. PACKER M, Anker SD, Butler J, Cleland JGF, et al
     Identification of three mechanistic pathways for iron-deficient heart failure.
     Eur Heart J. 2024 May 11:ehae284. doi: 10.1093.
     PubMed     Abstract available
     
     
     
217. CLEPHAS PRD, Zwartkruis VW, Malgie J, van Gent MWF, et al
     Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial.
     Eur Heart J. 2024 May 11:ehae323. doi: 10.1093.
     PubMed     Abstract available
     
     
     
218. WANG R, Schiattarella GG
     Tackling metabolic defects in HFpEF.
     Eur Heart J. 2024;45:1494-1496.
     PubMed    
     
     
     April 2024
219. NGO LTH, Peng Y, Denman R, Yang I, et al
     Long-term outcomes after hospitalization for atrial fibrillation or flutter.
     Eur Heart J. 2024 Apr 28:ehae204. doi: 10.1093.
     PubMed     Abstract available
     
     
     
220. JACKSON AM, Goland S, Farhan HA, Yaseen IF, et al
     A novel score to predict left ventricular recovery in peripartum cardiomyopathy derived from the ESC EORP Peripartum Cardiomyopathy Registry.
     Eur Heart J. 2024;45:1430-1439.
     PubMed     Abstract available
     
     
     
221. PALUDAN-MULLER C, Vad OB, Stampe NK, Diederichsen SZ, et al
     Atrial fibrillation: age at diagnosis, incident cardiovascular events, and mortality.
     Eur Heart J. 2024 Apr 9:ehae216. doi: 10.1093.
     PubMed     Abstract available
     
     
     
222. CREA F
     The complex interaction between cancer, ischaemic heart disease, and heart failure, and a focus on arrhythmias including risk stratification in Brugada syndrome and leadless pacing.
     Eur Heart J. 2024;45:1183-1187.
     PubMed    
     
     
     
223. RUZIEH M
     Comparative effectiveness research using claims data: meticulous methods don't solve old problems.
     Eur Heart J. 2024;45:1284.
     PubMed    
     
     
     
224. WU VC, Yeh JK, Chen SW, Wu CL, et al
     Syphilis and cardiovascular risk: a Taiwanese registry.
     Eur Heart J. 2024 Apr 3:ehae183. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2024
225. ALCOCER-GAMBA MA, Alvarez-Sangabriel A, de la Parra-Calderon JA
     Management of heart failure in Mexico: challenges and opportunities.
     Eur Heart J. 2024 Mar 29:ehae059. doi: 10.1093.
     PubMed    
     
     
     
226. PEDICINO D, Volpe M
     Weekly journal scan: a hard RAFTing to improve long-term survival in heart failure with severely reduced ejection fraction.
     Eur Heart J. 2024 Mar 28:ehae167. doi: 10.1093.
     PubMed    
     
     
     
227. WYLD M, Webster AC
     Myocardial infarction and stroke in patients with kidney failure: can we do better?
     Eur Heart J. 2024 Mar 27:ehae153. doi: 10.1093.
     PubMed    
     
     
     
228. SCHUERMANS A, Vlasschaert C, Nauffal V, Cho SMJ, et al
     Clonal haematopoiesis of indeterminate potential predicts incident cardiac arrhythmias.
     Eur Heart J. 2024;45:791-805.
     PubMed     Abstract available
     
     
     
229. CLELAND JGF, Kalra PA, Pellicori P, Graham FJ, et al
     Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.
     Eur Heart J. 2024 Mar 6:ehae086. doi: 10.1093.
     PubMed     Abstract available
     
     
     
230. CHAIX MA, Dore A, Mondesert B, Mongeon FP, et al
     Angiotensin receptor-neprilysin inhibitor vs. placebo in congenital systemic right ventricular heart failure: the PARACYS-RV trial.
     Eur Heart J. 2024 Mar 6:ehad890. doi: 10.1093.
     PubMed    
     
     
     
231. SAYOUR NV, Paal AM, Ameri P, Meijers WC, et al
     Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence.
     Eur Heart J. 2024 Mar 5:ehae105. doi: 10.1093.
     PubMed     Abstract available
     
     
     
232. MURARU D, Badano LP, Hahn RT, Lang RM, et al
     Atrial secondary tricuspid regurgitation: pathophysiology, definition, diagnosis, and treatment.
     Eur Heart J. 2024 Mar 5:ehae088. doi: 10.1093.
     PubMed     Abstract available
     
     
     
233. 
     Correction to: Conventional heart failure therapy in cardiac ATTR amyloidosis.
     Eur Heart J. 2024 Mar 1:ehae140. doi: 10.1093.
     PubMed    
     
     
     February 2024
234. ZURKAN D, Pitt B, Edelmann F
     Mineralocorticoid receptor antagonists for the prevention of atrial fibrillation in patients with and without heart failure: one more beneficial effect?
     Eur Heart J. 2024 Feb 6:ehae040. doi: 10.1093.
     PubMed    
     
     
     January 2024
235. BERNARDO MC, Carvalho SS, Moreira I
     Massive myocardial calcification as an aetiology of heart failure.
     Eur Heart J. 2024 Jan 23:ehae009. doi: 10.1093.
     PubMed    
     
     
     
236. BAUERSACHS J, de Boer RA, Zieroth S
     The year in cardiovascular medicine 2023: the top 10 papers in heart failure and cardiomyopathies.
     Eur Heart J. 2024 Jan 18:ehad878. doi: 10.1093.
     PubMed    
     
     
     
237. GALIUTO L, Volpe M
     A new RNA-interference based strategy is associated with mild beneficial effects in patients with heart failure due to cardiac amyloidosis.
     Eur Heart J. 2024 Jan 18:ehae015. doi: 10.1093.
     PubMed    
     
     
     
238. DOEHNER W, Akyea RK, Ntaios G
     The obesity paradigm on outcome in heart failure with reduced ejection fraction.
     Eur Heart J. 2024 Jan 18:ehad761. doi: 10.1093.
     PubMed    
     
     
     
239. BUTT JH, McMurray JJV
     The obesity paradigm on outcome in heart failure with reduced ejection fraction.
     Eur Heart J. 2024 Jan 18:ehad764. doi: 10.1093.
     PubMed    
     
     
     
240. AHN HJ, An HY, Ryu G, Lim J, et al
     Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study.
     Eur Heart J. 2024 Jan 17:ehad869. doi: 10.1093.
     PubMed     Abstract available
     
     
     
241. PELLICORI P, Hunter D, Ei Khin HH, Cleland JGF, et al
     How to diagnose and treat venous congestion in heart failure.
     Eur Heart J. 2024 Jan 9:ehad883. doi: 10.1093.
     PubMed    
     
     
     
242. ORAII A, Healey JS, Kowalik K, Pandey AK, et al
     Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials.
     Eur Heart J. 2024 Jan 9:ehad811. doi: 10.1093.
     PubMed     Abstract available
     
     
     
243. KAMBIC T, Lavie CJ, Eijsvogels TMH
     Seeking synergy for novel weight- and glucose-lowering pharmacotherapy and exercise training in heart failure patients with preserved ejection fraction.
     Eur Heart J. 2024 Jan 8:ehad856. doi: 10.1093.
     PubMed    
     
     
     December 2023
244. 
     Correction to: Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry.
     Eur Heart J. 2023 Dec 21:ehad855. doi: 10.1093.
     PubMed    
     
     
     
245. ABU-OWN H, Webb I, Okonko DO
     Intravenous iron repletion in heart failure: bridging the gap between symptom relief and hard clinical outcomes.
     Eur Heart J. 2023;44:5092-5094.
     PubMed    
     
     
     
246. KRAMARENKO D, Walsh R
     Emery-Dreifuss muscular dystrophy: a closer look at cardiac complications.
     Eur Heart J. 2023;44:5074-5076.
     PubMed    
     
     
     
247. LI XM, Zhu XJ, Jing ZC
     Reverse cardiac remodelling after balloon atrial septostomy for pulmonary arterial hypertension and end-stage heart failure.
     Eur Heart J. 2023 Dec 16:ehad822. doi: 10.1093.
     PubMed    
     
     
     
248. MULLER FS, Aherrahrou Z, Grasshoff H, Heidorn MW, et al
     Autoantibodies against the chemokine receptor 3 predict cardiovascular risk.
     Eur Heart J. 2023;44:4935-4949.
     PubMed     Abstract available
     
     
     
249. MEHRA MR, Castagna F, Butler J
     The transformative potential of left ventricular assist devices in advanced heart failure: no more a therapeutic orphan.
     Eur Heart J. 2023 Dec 11:ehad555. doi: 10.1093.
     PubMed    
     
     
     
250. KHAN MS, Usman MS, Van Spall HGC, Greene SJ, et al
     Endpoint adjudication in cardiovascular clinical trials.
     Eur Heart J. 2023;44:4835-4846.
     PubMed     Abstract available
     
     
     
251. WESTWOOD M, Almeida AG, Barbato E, Delgado V, et al
     Competency-based cardiac imaging for patient-centred care. A statement of the European Society of Cardiology (ESC). With the contribution of the European Association of Cardiovascular Imaging (EACVI), and the support of the Association of Cardiovascul
     Eur Heart J. 2023;44:4771-4780.
     PubMed     Abstract available
     
     
     November 2023
252. SCHMITTO JD, Shaw S, Garbade J, Gustafsson F, et al
     Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry.
     Eur Heart J. 2023 Nov 30:ehad658. doi: 10.1093.
     PubMed     Abstract available
     
     
     
253. 
     Correction to: 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of
     Eur Heart J. 2023 Nov 23:ehad613. doi: 10.1093.
     PubMed    
     
     
     
254. CREA F
     Fighting the pandemic of heart failure: better utilization of current treatments, new drugs, and new therapeutic targets.
     Eur Heart J. 2023;44:4607-4611.
     PubMed    
     
     
     
255. TOMII D, Praz F, Windecker S
     Guideline directed medical therapy in patients with heart failure undergoing transcatheter edge-to-edge mitral valve repair: unfulfilled premise.
     Eur Heart J. 2023 Nov 15:ehad678. doi: 10.1093.
     PubMed    
     
     
     
256. HENRY CM, Oseran AS, Zheng Z, Dong H, et al
     Cardiovascular Hospitalizations and Mortality Among Adults Aged 25 to 64 years in the United States.
     Eur Heart J. 2023 Nov 11:ehad772. doi: 10.1093.
     PubMed     Abstract available
     
     
     
257. JESSEN N, Mocumbi AO, Sliwa K
     Heart failure in Africa: challenges of dealing with a heterogeneous syndrome in a heterogeneous continent.
     Eur Heart J. 2023 Nov 9:ehad742. doi: 10.1093.
     PubMed    
     
     
     
258. WERT L, Falk V, Potapov EV
     Severe aortic regurgitation after short-term treatment with microaxial left ventricular assist device in the transaxillary approach.
     Eur Heart J. 2023 Nov 9:ehad750. doi: 10.1093.
     PubMed    
     
     
     
259. KIYUNA LA, Candido DS, Bechara LRG, Jesus ICG, et al
     4-Hydroxynonenal impairs miRNA maturation in heart failure via Dicer post-translational modification.
     Eur Heart J. 2023 Nov 7:ehad662. doi: 10.1093.
     PubMed     Abstract available
     
     
     
260. SLUIJTER JPG, Xiao J
     Post-translational modifications upon mitochondrial dysfunction in heart failure.
     Eur Heart J. 2023 Nov 6:ehad710. doi: 10.1093.
     PubMed    
     
     
     
261. INCIARDI RM, Solomon SD
     Beyond the rhythm: atrial fibrillation, diastolic dysfunction, and heart failure.
     Eur Heart J. 2023 Nov 3:ehad747. doi: 10.1093.
     PubMed    
     
     
     October 2023
262. RESTIVO A, Paglianiti DA, D'Amario D
     Left atrial pressure-assisted acute heart failure management in the cardiac intensive care unit: a proof-of-concept.
     Eur Heart J. 2023 Oct 26:ehad730. doi: 10.1093.
     PubMed    
     
     
     
263. LIUZZO G, Patrono C
     Moving a STEP forward in the treatment of patients with obesity and heart failure with preserved ejection fraction.
     Eur Heart J. 2023 Oct 25:ehad674. doi: 10.1093.
     PubMed    
     
     
     
264. CREA F
     Innovative trials in heart failure, dyslipidaemias, and sinus node dysfunction.
     Eur Heart J. 2023;44:4203-4207.
     PubMed    
     
     
     
265. PANDEY A, Kolkailah AA, Cosentino F, Cannon CP, et al
     Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
     Eur Heart J. 2023 Oct 21:ehad639. doi: 10.1093.
     PubMed    
     
     
     
266. DENIAU B, Costanzo MR, Sliwa K, Asakage A, et al
     Acute heart failure: current pharmacological treatment and perspectives.
     Eur Heart J. 2023 Oct 18:ehad617. doi: 10.1093.
     PubMed     Abstract available
     
     
     
267. PEDICINO D, Volpe M
     Atrial fibrillation ablation improves outcomes in patients with end-stage heart failure: is it all gold the glitter in the CASTLE?
     Eur Heart J. 2023 Oct 17:ehad675. doi: 10.1093.
     PubMed    
     
     
     
268. CAI A, Qiu W, Xia S, Zhou Y, et al
     Sex-specific characteristics and outcomes in hospitalized heart failure with preserved ejection fraction: the China Cardiovascular Association Database-Heart Failure Center Registry.
     Eur Heart J. 2023 Oct 4:ehad619. doi: 10.1093.
     PubMed    
     
     
     
269. CREA F
     Focus on heart failure and cardiomyopathies: new ESC Guidelines and key meta-analyses.
     Eur Heart J. 2023;44:3487-3491.
     PubMed    
     
     
     September 2023
270. BORLAUG BA, Schaff HV, Asirvatham SJ, Koepp KE, et al
     Surgical pericardiotomy to treat heart failure with preserved ejection fraction: a first clinical study.
     Eur Heart J. 2023 Sep 22:ehad620. doi: 10.1093.
     PubMed    
     
     
     
271. MOHANTY S, La Fazia VM, Natale A
     The Antwerp score: is this the 'new hope on the horizon'?
     Eur Heart J. 2023;44:3336-3338.
     PubMed    
     
     
     
272. PANDEY AK, Bhatt DL, Pandey A, Marx N, et al
     Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction.
     Eur Heart J. 2023 Sep 7:ehad389. doi: 10.1093.
     PubMed     Abstract available
     
     
     
273. CREA F
     Hot topics in congenital heart disease: tetralogy of Fallot, Ross operation, immunodeficiency, cardiac arrest, and end-stage heart failure.
     Eur Heart J. 2023;44:3201-3204.
     PubMed    
     
     
     
274. LADOUCEUR M
     Congenitally corrected transposition of the great arteries: have we shifted the disease 'trajectory?
     Eur Heart J. 2023;44:3292-3294.
     PubMed    
     
     
     
275. ANGERMANN CE, Ertl G
     Remote heart failure management guided by pulmonary artery pressure home monitoring: rewriting the future?
     Eur Heart J. 2023 Sep 6:ehad525. doi: 10.1093.
     PubMed    
     
     
     
276. BROWNELL NK, Fonarow GC
     Hospitalization for heart failure requires a PROMPT response.
     Eur Heart J. 2023 Sep 6:ehad444. doi: 10.1093.
     PubMed    
     
     
     August 2023
277. GHAZI L, Yamamoto Y, Fuery M, O'Connor K, et al
     Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial.
     Eur Heart J. 2023 Aug 31:ehad512. doi: 10.1093.
     PubMed     Abstract available
     
     
     
278. LEONG DP, Joseph P, McMurray JJV, Rouleau J, et al
     Frailty and outcomes in heart failure patients from high-, middle- and low-Income countries.
     Eur Heart J. 2023 Aug 28:ehad595. doi: 10.1093.
     PubMed     Abstract available
     
     
     
279. CANNIE DE, Syrris P, Protonotarios A, Bakalakos A, et al
     Emery-Dreifuss Muscular Dystrophy 1 is associated with high risk of malignant ventricular arrhythmias and end-stage heart failure.
     Eur Heart J. 2023 Aug 28:ehad561. doi: 10.1093.
     PubMed     Abstract available
     
     
     
280. MCALISTER FA
     Frailty: A new Vital Sign in Heart Failure Comes of age.
     Eur Heart J. 2023 Aug 28:ehad559. doi: 10.1093.
     PubMed    
     
     
     
281. NASER JA, Lee E, Scott CG, Kennedy AM, et al
     Prevalence and Incidence of Diastolic Dysfunction in Atrial Fibrillation: Clinical Implications.
     Eur Heart J. 2023 Aug 28:ehad592. doi: 10.1093.
     PubMed     Abstract available
     
     
     
282. VARSHNEY AS, Shah M, Vemulapalli S, Kosinski A, et al
     Heart Failure Medical Therapy Prior to Mitral Transcatheter Edge-to-Edge Repair: The STS/ACC Transcatheter Valve Therapy Registry.
     Eur Heart J. 2023 Aug 26:ehad584. doi: 10.1093.
     PubMed     Abstract available
     
     
     
283. MERKELY B, Hatala R, Wranicz JK, Duray G, et al
     Upgrade of right ventricular pacing to cardiac resynchronisation therapy in heart failure: a randomised trial.
     Eur Heart J. 2023 Aug 26:ehad591. doi: 10.1093.
     PubMed     Abstract available
     
     
     
284. LINDE C
     The BUDAPEST trial: a good grade for upgrades in heart failure with reduced ejection fraction.
     Eur Heart J. 2023 Aug 26:ehad588. doi: 10.1093.
     PubMed    
     
     
     
285. PONIKOWSKI P, Mentz RJ, Hernandez AF, Butler J, et al
     Efficacy of Ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.
     Eur Heart J. 2023 Aug 26:ehad586. doi: 10.1093.
     PubMed     Abstract available
     
     
     
286. BUENO H, Packer M
     Acetazolamide for Acute Heart Failure: Is ADVOR a Riddle Wrapped in a Mystery Inside an Enigma?
     Eur Heart J. 2023 Aug 25:ehad560. doi: 10.1093.
     PubMed    
     
     
     
287. MEEKERS E, Dauw J, Martens P, Dhont S, et al
     Renal Function and Decongestion With Acetazolamide in Acute Decompensated Heart Failure: The ADVOR Trial.
     Eur Heart J. 2023 Aug 25:ehad557. doi: 10.1093.
     PubMed     Abstract available
     
     
     
288. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
     2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
     Eur Heart J. 2023 Aug 25:ehad195. doi: 10.1093.
     PubMed    
     
     
     
289. WU J, Nadarajah R, Nakao YM, Nakao K, et al
     Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation.
     Eur Heart J. 2023 Aug 25:ehad571. doi: 10.1093.
     PubMed     Abstract available
     
     
     
290. BAUERSACHS J, Soltani S
     Sodium-glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists synergism in heart failure: it takes two to tango.
     Eur Heart J. 2023 Aug 23:ehad540. doi: 10.1093.
     PubMed    
     
     
     
291. BANERJEE M, Maisnam I, Pal R, Mukhopadhyay S, et al
     Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
     Eur Heart J. 2023 Aug 22:ehad522. doi: 10.1093.
     PubMed     Abstract available
     
     
     
292. VAN DISSEL AC, Opotowsky AR, Burchill LJ, Aboulhosn J, et al
     End-stage heart failure in congenitally corrected transposition of the great arteries: a multicentre study.
     Eur Heart J. 2023 Aug 18:ehad511. doi: 10.1093.
     PubMed     Abstract available
     
     
     
293. CREA F
     Late breaking trials in heart failure.
     Eur Heart J. 2023;44:2877-2882.
     PubMed    
     
     
     
294. MARTENS P, Testani J, Damman K
     Prevention and treatment of diuretic resistance in acute heart failure: when to use which combination of diuretics?
     Eur Heart J. 2023;44:2978-2981.
     PubMed    
     
     
     
295. CHENG RK, Cuddy SAM
     Neurohormonal blockade in transthyretin amyloidosis: perhaps one size does not fit all?
     Eur Heart J. 2023;44:2908-2910.
     PubMed    
     
     
     
296. BAYES-GENIS A, Pascual-Figal D
     Making STRONGer the transition phase: personalized GDMT through NT-proBNP monitoring.
     Eur Heart J. 2023;44:2963-2965.
     PubMed    
     
     
     
297. NADARAJAH R, Nakao YM, Wu J, Gale CP, et al
     Using routinely collected health record data for the earlier detection of heart failure with preserved ejection fraction: FIND-HFpEF.
     Eur Heart J. 2023 Aug 3:ehad440. doi: 10.1093.
     PubMed    
     
     
     
298. LIN GM, Tsai KZ, Lavie CJ
     Waist-to-height ratio for the obesity paradox in heart failure: is it a matter of fitness?
     Eur Heart J. 2023 Aug 2:ehad503. doi: 10.1093.
     PubMed    
     
     
     
299. ROHDE LE, McMurray JJV
     REVIV(E)ing the ischaemic paradigm in heart failure: STICHes are needed.
     Eur Heart J. 2023 Aug 1:ehad488. doi: 10.1093.
     PubMed    
     
     
     July 2023
300. PEDICINO D, Volpe M
     New evidence supporting haemodynamics-guided remote management of congestion in heart failure.
     Eur Heart J. 2023 Jul 21:ehad435. doi: 10.1093.
     PubMed    
     
     
     
301. VERGALLO R, Patrono C
     Heart failure and socioeconomic status: global differences and inequalities.
     Eur Heart J. 2023 Jul 15:ehad410. doi: 10.1093.
     PubMed    
     
     
     
302. GREENE SJ, Fonarow GC
     Targeting sacubitril/valsartan for heart failure with mildly reduced or preserved ejection fraction.
     Eur Heart J. 2023 Jul 5:ehad427. doi: 10.1093.
     PubMed    
     
     
     
303. 
     Corrigendum to: Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.
     Eur Heart J. 2023 Jul 3:ehad406. doi: 10.1093.
     PubMed    
     
     
     June 2023
304. BERGONTI M, Ascione C, Marcon L, Pambrun T, et al
     Left ventricular functional recovery after atrial fibrillation catheter ablation in heart failure: a prediction model.
     Eur Heart J. 2023 Jun 30:ehad428. doi: 10.1093.
     PubMed     Abstract available
     
     
     
305. KOEHLER F, Hindricks G
     Is telemonitoring for heart failure ready after a journey longer than two decades?
     Eur Heart J. 2023 Jun 27:ehad395. doi: 10.1093.
     PubMed    
     
     
     
306. WITSCH J, Kasner SE
     Redefining the role of heart failure in stroke.
     Eur Heart J. 2023 Jun 26:ehad360. doi: 10.1093.
     PubMed    
     
     
     
307. YANG M, Kondo T, Butt JH, Abraham WT, et al
     Stroke in patients with heart failure and reduced or preserved ejection fraction.
     Eur Heart J. 2023 Jun 26:ehad338. doi: 10.1093.
     PubMed     Abstract available
     
     
     
308. CREA F
     Challenges and opportunities in the management of acute heart failure and cardiac amyloidosis.
     Eur Heart J. 2023;44:2135-2139.
     PubMed    
     
     
     
309. ARNOTT C, Neal B
     Good for your heart and safe for your toes: a patient-level meta-analysis of DAPA-HF and DELIVER.
     Eur Heart J. 2023;44:2184-2186.
     PubMed    
     
     
     
310. TOLOMEO P, Butt JH, Kondo T, Campo G, et al
     Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial.
     Eur Heart J. 2023;44:2202-2212.
     PubMed     Abstract available
     
     
     
311. PEDICINO D, Vergallo R
     Long-lasting effects of transcatheter repair of secondary mitral regurgitation: the latest lesson from COAPT trial.
     Eur Heart J. 2023 Jun 14:ehad349. doi: 10.1093.
     PubMed    
     
     
     
312. JANKOWSKA EA, Ponikowski P
     Acyl-ghrelin therapy for heart failure: already a novel inotrope or even more?
     Eur Heart J. 2023;44:2026-2028.
     PubMed    
     
     
     
313. CREA F
     Addressing the pandemic of heart failure: old and new therapeutic opportunities.
     Eur Heart J. 2023;44:1961-1964.
     PubMed    
     
     
     
314. MARTENS P, Verbrugge FH, Dauw J, Nijst P, et al
     Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial.
     Eur Heart J. 2023;44:1995-2005.
     PubMed     Abstract available
     
     
     
315. MAHMOOD SS, Riedell PA, Feldman S, George G, et al
     Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.
     Eur Heart J. 2023;44:2029-2042.
     PubMed     Abstract available
     
     
     
316. MARTENS P, Yu S, Larive B, Borlaug BA, et al
     Iron deficiency in pulmonary vascular disease: pathophysiological and clinical implications.
     Eur Heart J. 2023;44:1979-1991.
     PubMed     Abstract available
     
     
     
317. CAMPBELL RT, Docherty KF
     Serum bicarbonate and congestion: a potential biomarker for identifying and guiding management in diuretic resistance?
     Eur Heart J. 2023;44:2006-2008.
     PubMed    
     
     
     
318. MARX N, Muller-Wieland D
     SGLT2 inhibitors in heart failure and type 2 diabetes: from efficacy in trials towards effectiveness in the real world.
     Eur Heart J. 2023 Jun 8:ehad282. doi: 10.1093.
     PubMed    
     
     
     
319. FU EL, Patorno E, Everett BM, Vaduganathan M, et al
     Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
     Eur Heart J. 2023 Jun 1:ehad273. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2023
320. 
     Correction to: The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies.
     Eur Heart J. 2023 May 24:ehad307. doi: 10.1093.
     PubMed    
     
     
     
321. BUTT JH, Kondo T, Yang M, Jhund PS, et al
     Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.
     Eur Heart J. 2023 May 23:ehad276. doi: 10.1093.
     PubMed     Abstract available
     
     
     
322. CHATUR S, Vaduganathan M, Claggett B, Vardeny O, et al
     Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
     Eur Heart J. 2023 May 23:ehad283. doi: 10.1093.
     PubMed     Abstract available
     
     
     
323. BORLAUG BA, Testani JM
     SGLT2 inhibitors and Diuretics in Heart Failure: Clicking Reset on the Renal Volume Setpoint?
     Eur Heart J. 2023 May 23:ehad345. doi: 10.1093.
     PubMed    
     
     
     
324. ADAMO M, Pagnesi M, Mebazaa A, Davison B, et al
     NT-proBNP and high-intensity care for acute heart failure: the STRONG-HF trial.
     Eur Heart J. 2023 May 22:ehad335. doi: 10.1093.
     PubMed     Abstract available
     
     
     
325. IOANNOU A, Massa P, Patel RK, Razvi Y, et al
     Conventional heart failure therapy in cardiac ATTR amyloidosis.
     Eur Heart J. 2023 May 22:ehad347. doi: 10.1093.
     PubMed     Abstract available
     
     
     
326. SCHOLTE NTB, Gurgoze MT, Aydin D, Theuns DAMJ, et al
     Telemonitoring for heart failure: a meta-analysis.
     Eur Heart J. 2023 May 22:ehad280. doi: 10.1093.
     PubMed     Abstract available
     
     
     
327. CLEPHAS PRD, Radhoe SP, Boersma E, Gregson J, et al
     Efficacy of Pulmonary Artery Pressure Monitoring in Patients with Chronic Heart Failure: A Meta-Analysis of Three Randomized Controlled Trials.
     Eur Heart J. 2023 May 21:ehad346. doi: 10.1093.
     PubMed     Abstract available
     
     
     
328. VADUGANATHAN M, Mentz RJ, Claggett BL, Miao ZM, et al
     Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
     Eur Heart J. 2023 May 21:ehad344. doi: 10.1093.
     PubMed     Abstract available
     
     
     
329. ERN YEOH S, Osmanska J, Petrie MC, Brooksbank KJM, et al
     Dapagliflozin versus metolazone in heart failure resistant to loop diuretics.
     Eur Heart J. 2023 May 21:ehad341. doi: 10.1093.
     PubMed     Abstract available
     
     
     
330. DAMMAN K
     Risk of knowing too much: the tricky case of estimated glomerular filtration rate and treatment decisions in heart failure.
     Eur Heart J. 2023 May 20:ehad284. doi: 10.1093.
     PubMed    
     
     
     
331. MULLENS W, Schulze PC, Westphal J, Bogoviku J, et al
     Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice.
     Eur Heart J. 2023 May 19:ehad266. doi: 10.1093.
     PubMed    
     
     
     
332. 
     Corrigendum to: Reduced lean body mass: a potential modifiable contributor to the pathophysiology of heart failure.
     Eur Heart J. 2023 May 8:ehad272. doi: 10.1093.
     PubMed    
     
     
     
333. CREA F
     Heart failure with preserved ejection fraction: innovative diagnostic approaches and therapeutic targets.
     Eur Heart J. 2023;44:1481-1485.
     PubMed    
     
     
     
334. LEHTONEN J, Uusitalo V, Poyhonen P, Mayranpaa MI, et al
     Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis.
     Eur Heart J. 2023;44:1495-1510.
     PubMed     Abstract available
     
     
     
335. LEE SY, Chang S, Youn JC
     Successful management of aortic root thrombosis in a patient with Heartmate 3.
     Eur Heart J. 2023;44:1578.
     PubMed    
     
     
     April 2023
336. XIN Y, Li J, Li H
     Combination diuretic therapy in acute heart failure.
     Eur Heart J. 2023 Apr 21:ehad189. doi: 10.1093.
     PubMed    
     
     
     
337. TRULLAS JC, Casado J, Morales-Rull JL
     Combination diuretic therapy in acute heart failure.
     Eur Heart J. 2023 Apr 21:ehad217. doi: 10.1093.
     PubMed    
     
     
     
338. 
     Erratum to: Iron deficiency in heart failure across the spectrum of left ventricular ejection fraction: dotting the i's.
     Eur Heart J. 2023 Apr 20:ehad232. doi: 10.1093.
     PubMed    
     
     
     
339. JALLOH MB, Granger CB, Fonarow GC, Van Spall HGC, et al
     Multi-level implementation strategies to improve uptake of evidence-based therapies in heart failure.
     Eur Heart J. 2023 Apr 15:ehad150. doi: 10.1093.
     PubMed    
     
     
     
340. SHERROD CF, Farr SL, Sauer AJ
     Overcoming treatment inertia for patients with heart failure: how do we build systems that move us from rest to motion?
     Eur Heart J. 2023 Apr 12:ehad169. doi: 10.1093.
     PubMed    
     
     
     
341. VAN VELDHUISEN DJ, Bauersachs J
     Digitalis in heart failure: declining use and ongoing outcome trials.
     Eur Heart J. 2023 Apr 8:ehad185. doi: 10.1093.
     PubMed    
     
     
     
342. CREA F
     The link among heart failure, chronic kidney disease, and cancer: new light shed on the complex patient.
     Eur Heart J. 2023;44:1099-1102.
     PubMed    
     
     
     March 2023
343. LAM CSP, Ho JE
     Do we need dedicated heart failure with preserved ejection fraction clinics?
     Eur Heart J. 2023 Mar 29:ehad172. doi: 10.1093.
     PubMed    
     
     
     
344. SATO R, von Haehling S
     Revisiting the obesity paradox in heart failure: what is the best anthropometric index to gauge obesity?
     Eur Heart J. 2023 Mar 22:ehad079. doi: 10.1093.
     PubMed    
     
     
     
345. BUTT JH, Petrie MC, Jhund PS, Sattar N, et al
     Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox.
     Eur Heart J. 2023 Mar 22:ehad083. doi: 10.1093.
     PubMed     Abstract available
     
     
     
346. PACKER M, Siddiqi TJ, Butler J
     Drugs that slow the progression of diabetic kidney disease: are renoprotective effects attenuated in heart failure?
     Eur Heart J. 2023 Mar 21:ehad158. doi: 10.1093.
     PubMed    
     
     
     
347. LIUZZO G, Volpe M
     TRANSFORM-HF closes the loop on diuretic therapy in heart failure.
     Eur Heart J. 2023 Mar 21:ehad124. doi: 10.1093.
     PubMed    
     
     
     
348. DIAZ-CANESTRO C, Ng HF, Yiu KH, Montero D, et al
     Reduced lean body mass: a potential modifiable contributor to the pathophysiology of heart failure.
     Eur Heart J. 2023 Mar 16:ehad130. doi: 10.1093.
     PubMed    
     
     
     
349. VERWERFT J, Soens L, Wynants J, Meysman M, et al
     Heart failure with preserved ejection fraction: relevance of a dedicated dyspnoea clinic.
     Eur Heart J. 2023 Mar 16:ehad141. doi: 10.1093.
     PubMed     Abstract available
     
     
     
350. PEDICINO D, Volpe M
     Improving care for heart failure patients by COACHing clinicians to use decision-support tools.
     Eur Heart J. 2023 Mar 16:ehad097. doi: 10.1093.
     PubMed    
     
     
     
351. RAO VN, Giczewska A, Chiswell K, Felker GM, et al
     Long-term outcomes of phenoclusters in severe tricuspid regurgitation.
     Eur Heart J. 2023 Mar 16:ehad133. doi: 10.1093.
     PubMed     Abstract available
     
     
     
352. LUND LH, Hage C, Pironti G, Thorvaldsen T, et al
     Acyl ghrelin improves cardiac function in heart failure and increases fractional shortening in cardiomyocytes without calcium mobilization.
     Eur Heart J. 2023 Mar 14:ehad100. doi: 10.1093.
     PubMed     Abstract available
     
     
     
353. TAYLOR RS, Dalal HM, Zwisler AD
     Cardiac rehabilitation for heart failure: 'Cinderella' or evidence-based pillar of care?
     Eur Heart J. 2023 Mar 11:ehad118. doi: 10.1093.
     PubMed     Abstract available
     
     
     
354. VERELST FR, Van Craenenbroeck EM, Gevaert AB
     Iron deficiency in heart failure across the spectrum of left ventricular ejection fraction: dotting the i's.
     Eur Heart J. 2023 Mar 9:ehad131. doi: 10.1093.
     PubMed    
     
     
     
355. SHEMESH E, Chevli PA, Islam T, German CA, et al
     Circulating ketone bodies and cardiovascular outcomes: the MESA study.
     Eur Heart J. 2023 Mar 6:ehad087. doi: 10.1093.
     PubMed     Abstract available
     
     
     
356. KAPELIOS CJ, Benson L, Crespo-Leiro MG, Anker SD, et al
     Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry.
     Eur Heart J. 2023 Mar 4:ehad109. doi: 10.1093.
     PubMed    
     
     
     February 2023
357. VOLPE M, Gallo G, Rubattu S
     Endocrine functions of the heart: from bench to bedside.
     Eur Heart J. 2023;44:643-655.
     PubMed     Abstract available
     
     
     
358. WOUTERS PC, van de Leur RR, Vessies MB, van Stipdonk AMW, et al
     Electrocardiogram-based deep learning improves outcome prediction following cardiac resynchronization therapy.
     Eur Heart J. 2023;44:680-692.
     PubMed     Abstract available
     
     
     January 2023
359. MARK PB, Carrero JJ, Matsushita K, Sang Y, et al
     Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study.
     Eur Heart J. 2023 Jan 24:ehac825. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2022
360. EL-CHOULI M, Meddis A, Christensen DM, Gerds TA, et al
     Lifetime risk of comorbidity in patients with simple congenital heart disease: a Danish nationwide study.
     Eur Heart J. 2022 Dec 7:ehac727. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2022
361. SCOTTI A, Coisne A, Taramasso M, Granada JF, et al
     Sex-Related Characteristics and Short-Term Outcomes of Patients Undergoing Transcatheter Tricuspid Valve Intervention for Tricuspid Regurgitation.
     Eur Heart J. 2022 Nov 29:ehac735. doi: 10.1093.
     PubMed     Abstract available
     
     
     
362. HAXHA S, Halili A, Malmborg M, Pedersen-Bjergaard U, et al
     Type 2 diabetes mellitus and higher rate of complete atrioventricular block: a Danish Nationwide Registry.
     Eur Heart J. 2022 Nov 26:ehac662. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum